Telomerase activity and human telomerase reverse transcriptase (hTERT) mRNA expression were investigated in cervical specimens and were correlated with cytologic findings and the presence of human papilloma virus (HPV) infection. Telomerase activity was evaluated by the telomeric repeat protocol assay and hTERT mRNA expression was evaluated by reverse transcriptase polymerase chain reaction (PCR). HPV DNA was detected by PCR, as well as restriction endonuclease digestion. HPV DNA was detected in all 82 specimens with abnormal cytologic findings and in 4 of 34 normal samples. Low-grade squamous intraepithelial lesions (LGSILs) were present in 74 of 82 specimens (90.2%) and high-grade squamous intraepithelial lesions (HGSILs) were present in 8 of 82 (9.75%) specimens. Seven of the eight HGSIL (87.5%) and 26 of 74 LGSIL (35.1%) specimens were hTERT positive, whereas all normal specimens were hTERT mRNA negative. Telomerase activity was detected in 21 of 74 (28.4%) LGSIL/atypical squamous epithelial cells of undetermined significance (ASCUS) and in five of eight (62.5%) HGSIL samples. A correlation was observed among telomerase activity, hTERT mRNA expression, and high-risk HPV infection in HGSIL samples (P < 0.001). High-risk HPV infection assessment showed 75% sensitivity and 72.2% specificity for HGSILs. Telomerase activity assessment in cervical smears showed sensitivity and negative predictive value (NPV) for HGSILs 62.5% and 96.7%, whereas specificity and positive predictive value (PPV) were 80.5% and 19.2%, respectively, hTERT mRNA expression assessment showed 87.5% sensitivity and 98.7% NPV for HGSILs, whereas specificity and PPV were 76% and 21.2%, respectively. Based on the above-described telomerase assessment values, it is suggested that the telomerase system might not be an appropriate diagnostic marker for cytology, given that the final evaluation must rely on a combination of all available test assessment data, clinical diagnosis, as well as the follow-up of all LGSIL samples that were positive for telomerase activation.
BoschFX, ManosMM, MuñozN, ShermanM, JansenMA, PetoJ, SchiffmanHM, MorenoV, KurmanR, ShahVK. International biological study on cervical cancer (IBSCC) study group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst87: 796–802, 1995.
3.
Zur HausenH. Papillomaviruses and cancer: from basic studies to clinical applications. Nat Rev Cancer2: 342–350, 2002.
4.
CuzickJ, SzarewskiA, TerryG, HoL, HanbyA, MaddoxP, AndersonM, KocjanG, SteeleST, GuillebaudJ. Human papillomavirus testing in primary cervical screening. Lancet345: 1533–1536, 1995
5.
BoschFX, LorinczA, MuñozN, MeijerCJLM, ShahKV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol55: 244–264, 2002.
6.
KazuoY, AshfaqR, JanN, Von VivianG, MilchgrubS, AshaR, JorgeAS, ShayWJ, AdiFG. Telomerase activity and expression of its RNA component in cervical lesions. Cancer82: 1319–1327, 2002.
7.
ParkTW, RiethdorfS, SchulzG, RiethdorfL, WrightT, LöningT. Clonal expansion and HPV-induced immortalization are early molecular alterations in cervical carcinogenesis. Anticancer Res23: 155–160, 2003.
8.
LimSH, KimJH, Londoño-VallejoA, BuiH, TubacherE, SolomonG, ParkJE, HorikawaI, KouprinaN, BarrettCJ, LarionovV. The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions. Oncogene21: 769–777, 2002.
9.
ZhangDK, NganHYS, ChengRYS, CheungANY, LiuSS, TsaoSW. Clinical significance of telomerase activation and telomere restriction fragment (TRF) in cervical cancer. Eur J Cancer35: 154–160, 1999.
10.
JarboeEA, LiawKL, ThompsonLC, HeinzDE, BakerPL, McGregorJA, DunnT, WoodsJE, ShroyerKR. Analysis of telomerase as a diagnostic biomarker of cervical dysplasia and carcinoma. Oncogene21: 664–673, 2002.
11.
YasumotoS, KunimuraC, KikuchiK, TaharaH, OhjiH, YamamotoH, IdeT, UtakojiT. Telomerase activity in normal human epithelial cells. Oncogene13: 433–439, 1996.
12.
JarboeEA, ThompsonLC, HeinzD, McGregorJA, ShroyerKR. Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma. Hum Pathol35 (4): 396–402, 2004.
13.
WolfKJ, FrancoLE, ArbeitMJ, ShroyerRK, WuTC, RunowiczDC, Tortolero-LunaG, HerreroR, CrumPC. Innovations in understanding the biology of cervical cancer. Cancer Suppl98: 2064–2069, 2003.
14.
ZhangA, ManerS, BetzR, AngströmT, StendahlU, BergmanF, ZetterbergA, WallinKL. Genetic alterations in cervical carcinomas: Frequent low-level amplifications of oncogenes are associated with human papillomavirus infection. Int J Cancer101: 427–433, 2002.
15.
UngerER, VernonSD, LeeRD, MillerLD, ReevesCW. Detection of human papillomavirus in archival tissues: comparison of in situ hybridization and polymerase chain reaction. J Histochem Cytochem46: 535–540, 1998.
16.
UlanerGA, HuJF, GiudiceCL, HoffmanRA. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res58: 4168–4172, 1998.
17.
CongYS, WenJ, BacchettiS. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet8: 137–142, 1999.
18.
AndersonS, SheraK, IhleJ, BillmanL, GolfB, GreerB, TamimiH, McDougallJ, KlingelhutzA. Telomerase activation in cervical cancer. Am J Pathol151: 25–31, 1997.
19.
Zur HausenH. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol186: 131–156, 1994.
20.
FerberMJ, MontoyaDP, YuC, AdercaI, McGeeA, ThorlandEC, NagomeyDM, GostoutBS, BurgartLJ, BoixL, BruixJ, McMahonBJ, CheungTH, ChungTHH, WongYF, SmithDI, RobertsLR. Intergrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancer. Oncogene22: 3813–3820, 2003.
21.
FrostM, BobakJB, GiananiR, NamK, ScottW, SpaldingCD, CassGL, ThompsonLC, EnomotoT, Lopez-UribeD, ShroyerRK. Localization of telomerase hTERT protein and hTR in benign mucosa, dysplasia, and squamous cell carcinoma of the cervix. Am J Clin Pathol114: 726–734, 2000.
22.
HowardM, SellorsWJ, LytwynA, RothP, MahonyBJ. Combining human papillomavirus testing or cervicography with cytology to detect cervical neoplasia. Arch Pathol Lab Med128: 1257–1262, 2004.
23.
ASCUS-LSIL Triage Study (ALTS) Group.Results of a randomized trial on the management of cytology interpretations of atypical squamous epithelial cells of undetermined significance. Am J Obstet Gynecol188: 1383–1392, 2003.
24.
LytwynA, SellorsJW, MahonyJB, DayaD, ChapmanW, HowardM, RothP, LorinczAT, GafniA, WalterSD. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med127: 1169–1175, 2003.
25.
CheahPL, LooiLM, NgMH, SivanesaratnamV. Telomerase activation and human papillomavirus infection in invasive uterine cervical carcinoma in a set of Malaysian patients. J Clin Pathol55: 22–26, 2002.
26.
MutiranguraA, SriuranpongV, TermrunggraunglertW, TresukosolD, Lertsaguansinchai, VoravudN, NiruthisardS. Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Cancer78: 933–939, 1998.
27.
KawaiK, YaginumaY, TsuruokaH, GriffinM, HayashiH, IshikawaM. Telomerase activity and human papillomavirus (HPV) infection in human uterine cervical cancers and cervical smears. Eur J Cancer34: 2082–2086, 1998.
28.
WismanGB, HollemaH, de JongS, ter ScheggetJ, Tjong-A-HungSP, RuitersMH, KransM, de VriesEG, van der ZeeAG. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol16: 2238–2245, 1998.
29.
SnijdersPJF, Van DuinM, WalboomersMMJ, SteenbergerDMR, RisseKJE, HelmerhorstJMT, VerheijenHMR, MeijerJLMC. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res58: 3812–3818, 1998.
30.
WismanGB, KnolJA, HelderNM, KransM, De VriesGEE, HollemaH, JongDES, Van Der ZeeGJA. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer91: 658–664, 2001.
31.
Reesink-PetersN, HelderMN, WismanGB, KnolAJ, KoopmansS, BoezenHM, SchuuringE, HollemaH, de VriesEG, de JongS, van der ZeeAG. Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol56: 31–35, 2003.
32.
RiethdorfS, RiethdorfL, ShulzG, IkendergH, JänickeF, LöningT, ParkTW. Relationship between telomerase activation and HPV16/18 oncogene expression in squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix. Int J Gynecol Pathol20: 177–185, 2001.
33.
LanhamS, HerbertA, WalttP. HPV detection and measurement of HPV-16 telomerase and surviving transcripts in colposcopy clinic patients. J Clin Pathol54: 304–308, 2001
34.
FaheyMT, IwigL, MacaskillP. Meta-analysis of Pap test accuracy. Am J Epidemiol141: 680–9, 1995.
35.
KyoS, TakamuraM, IshikawaH, SasagawaT, SatakeS, TatenoM, InoueM. Application of telomerase assay for the screening of cervical lesions. Cancer Res57: 1863–1867, 1997.
36.
GorhamH, YoshidaK, SuginoT, MarschG, ManekS, ChamockM, TarinD, DoodisonS. Telomerase activity in human gynecological malignancies. J Clin Pathol50: 501–504, 1997.
37.
ZhengPS, IwasakaT, YokohamaM, NakaoY, PaterA, SugimoriH. Telomerase activation in in vitro and in vivo cervical carcinogenesis. Gynecol Oncol66: 222–226, 1997.
